Inflammasome Reports Positive Phase 2 K8 Results
NEWTON, Mass., July 17, 2026 Inflammasome Therapeutics announced positive six-month Phase 2 clinical trial results for K8 (kamuvudine-8), its...
AMD
Advertisement
Silo Pharma Advances AI Through AMD Program
SARASOTA, Fla., July 14, 2026 Silo Pharma announced that its wholly owned subsidiary, QwikAgents, has been accepted into AMD’s...
Annexon Advances Vonaprument with Phase 2 Data
BRISBANE, Calif., July 14, 2026 Annexon announced that new analyses from its Phase 2 ARCHER trial evaluating vonaprument in...
Renerva Implants First PNM-CAP Device for Neuroma Pain
PITTSBURGH, May 13, 2026 Renerva, Inc. announced the successful first-in-human implantation of its investigational PNM-CAP™ device, marking a major...
Astellas Reports IZERVAY Reduced Vision Decline in GA Patients
NORTHBROOK, Ill., May 12, 2026 Astellas Pharma US announced new clinical findings showing that IZERVAY® (avacincaptad pegol intravitreal solution)...
Advertisements
Merck Launches Phase 2b/3 Trial for AMD Eye Therapy
RAHWAY, N.J., April 2, 2026 Merck (MSD) has announced the initiation of a pivotal Phase 2b/3 clinical trial (MALBEC)...
i-Lumen Advances AMD Trial With FDA IDE Approval
BLOOMINGTON, Minn., USA, March 31, 2026 i-Lumen Scientific has received FDA Investigational Device Exemption (IDE) approval to initiate U.S....
Advertisement
